for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tricida Inc

TCDA.OQ

Latest Trade

7.66USD

Change

0.18(+2.41%)

Volume

150,433

Today's Range

7.55

 - 

7.90

52 Week Range

3.74

 - 

44.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.48
Open
7.58
Volume
150,433
3M AVG Volume
24.43
Today's High
7.90
Today's Low
7.55
52 Week High
44.25
52 Week Low
3.74
Shares Out (MIL)
50.18
Market Cap (MIL)
375.38
Forward P/E
-1.41
Dividend (Yield %)
--

Next Event

Q4 2020 Tricida Inc Earnings Release

Latest Developments

More

Morgan Stanley Reports 5.7% Passive Stake In Tricida Inc

Tricida Q3 Loss Per Share $1.55

Tricida Says Significantly Reducing Its Headcount From 152 To 59 People

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tricida Inc

Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.

Industry

Biotechnology & Drugs

Contact Info

7000 Shoreline Ct Ste 201

SOUTH SAN FRANCISCO, CA

94080-7603

United States

+1.415.4297800

https://www.tricida.com/

Executive Leadership

Klaus R. Veitinger

Independent Chairman of the Board

Gerrit Klaerner

President, Chief Executive Officer, Director

Geoffrey M. Parker

Chief Financial Officer, Executive Vice President

Robert McKague

Executive Vice President, General Counsel, Secretary

Dawn Parsell

Executive Vice President - Clinical Development

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-4.640

2019

-3.720

2020(E)

-5.320
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
119.61
LT Debt To Equity (MRQ)
111.08
Return on Investment (TTM)
-75.30
Return on Equity (TTM)
-68.76

Latest News

Latest News

BRIEF-Tricida Prices Offering Of $175 Million 3.50% Convertible Senior Notes Due 2027

* TRICIDA PRICES OFFERING OF $175 MILLION 3.50% CONVERTIBLE SENIOR NOTES DUE 2027 Source text for Eikon: Further company coverage:

BRIEF-Tricida Reports Proposed Offering Of $175 Mln Convertible Senior Notes Due 2027

* TRICIDA ANNOUNCES PROPOSED OFFERING OF $175 MILLION CONVERTIBLE SENIOR NOTES DUE 2027 Source text for Eikon: Further company coverage:

BRIEF-Tricida Announces First Quarter 2020 Financial Results

* Q1 EARNINGS PER SHARE ESTIMATE $-1.40 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

BRIEF-Tricida Committed To Seeking FDA Approval For Commercialization Of Veverimer As Treatment For Metabolic Acidosis

* TRICIDA - COMMITTED TO SEEKING FDA APPROVAL, TO PREPARING FOR COMMERCIALIZATION OF VEVERIMER AS TREATMENT FOR METABOLIC ACIDOSIS

BRIEF-Tricida Hires Robert McKague As Executive Vice President, General Counsel & Chief Compliance Officer

* TRICIDA HIRES ROBERT MCKAGUE AS EXECUTIVE VICE PRESIDENT, GENERAL COUNSEL & CHIEF COMPLIANCE OFFICER Source text for Eikon: Further company coverage:

BRIEF-Tricida Reports Q4 Loss Per Share $1.17

* TRICIDA ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up